Anavex Life Sciences Corp (AVXL)

[OFP]

This is very interesting imho. Could it relate to A2-73?

“Recent studies demonstrate that the therapeutic response in AD is genotype-specific. Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2. Approximately, 15%–20% of the AD population may exhibit an abnormal metabolism of AChEIs; about 50% of this population cluster would show an ultrarapid metabolism, requiring higher doses of AChEIs to reach a therapeutic threshold, whereas the other 50% of the cluster would exhibit a poor metabolism, displaying potential adverse events at low doses.

Essentially all were on the MTD and AVXL analyzed their data based on plasma levels not dose. Would expect that as a result genetic factors impacting metabolic rate would have minimal impact on their findings.